Biogen's multiple sclerosis dominance and emerging neurology pipeline create a wide moat.
Biogen’s full-year 2017 performance (revenue growth excluding hemophilia of 15% and non-GAAP EPS growth of 8%) was slightly ahead of our expectations, but 2018 guidance for $12.7 billion-$13 billion in revenue and non-GAAP EPS of $24.20-$25.20 are both significantly ahead of our expectations, largely because of the rapid ramp-up for Spinraza sales. After accounting for a longer runways for Biogen’s oral MS franchise (with the ALKS 8700 rights), stronger Spinraza sales in 2018-19, and a slightly ...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.